Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company pioneering tumor-activated therapies designed to target cancer precisely while reducing systemic side effects. This page serves as the definitive source for verified news and press releases related to XLO’s innovative immuno-oncology pipeline and strategic developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and research partnerships. Our curated collection includes announcements about XLO’s proprietary platform, engineered therapies (including cytokines, antibodies, and bispecifics), and collaborations advancing targeted cancer treatments.
Key updates cover advancements in tumor-activated IL-12, CTLA-4 inhibitors, and T cell engagers – all leveraging XLO’s focus on activating therapies exclusively within the tumor microenvironment. Bookmark this page to stay informed about developments that highlight the company’s scientific rigor and position in the competitive biotech landscape.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced the granting of stock options to three new employees. The Compensation Committee approved non-qualified stock options to purchase 101,000 shares of common stock under the company's 2022 Inducement Stock Incentive Plan. These options, effective October 1, 2024, have an exercise price of $0.75 per share, matching the closing price on that date. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employment.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's president and CEO, René Russo, Pharm.D., will engage in a fireside chat on September 4, 2024, at 7:00 am EDT.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's website. The webcast will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the company's latest developments and strategies in the field of cancer treatment.
Xilio Therapeutics (Nasdaq: XLO) reported Q2 2024 financial results and pipeline updates. Key highlights include:
1. Initiated Phase 2 trial of XTX101 with atezolizumab in MSS CRC patients.
2. Started Phase 1B monotherapy dose expansion for XTX301 in advanced solid tumors.
3. Expects to report clinical data for XTX101 and XTX301 in Q4 2024.
4. Q2 2024 ended with $74.9 million in cash, anticipating runway into Q2 2025.
5. Q2 2024 financial results: $2.4 million license revenue, $11.2 million R&D expenses, $5.8 million G&A expenses, $13.9 million net loss.
6. Promoted Chris Frankenfield to CFO while retaining COO role.
7. Advancing research-stage tumor-activated bispecifics and immune cell engagers.
Xilio Therapeutics, a clinical-stage biotechnology firm, has announced the appointment of Dr. Aoife Brennan and Dr. James Shannon to its board of directors as of June 13, 2024.
Dr. Brennan brings over 16 years of industry leadership, having held executive roles at Synlogic and Biogen, while Dr. Shannon has over 30 years of experience, previously serving as chief medical officer at GlaxoSmithKline and holding leadership positions at Novartis.
Their extensive expertise is expected to significantly contribute to Xilio's ongoing development of novel, tumor-activated immuno-oncology therapies, with several clinical milestones anticipated in the near term.
Xilio Therapeutics (NASDAQ: XLO) announced significant pipeline and business updates alongside its Q1 2024 financial results. Highlighting their progress, they plan to initiate a Phase 2 trial for XTX101, an Fc-enhanced anti-CTLA-4, in combination with atezolizumab for MSS CRC in Q3 2024, and report clinical data in Q4 2024. The XTX301 IL-12 program, partnered with Gilead Sciences, received $43.5M upfront and is set for Phase 1 data release in Q4 2024. Furthermore, Xilio's research efforts on bispecifics and immune cell engagers are advancing. Financially, Xilio ended Q1 2024 with $34M in cash, supplemented by an additional $44.6M from Gilead agreements and private placements, projecting a cash runway until Q2 2025.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
